Patient Age, Tumor Appearance and Tumor Size Are Risk Factors for Early Recurrence of Cervical Cancer

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2015 Mar 24

PMID 25798268

Citations 20

Authors

Juan Wang

Tao Wang

Yun-Yi Yang

Yan-Lan Chai

Fan Shi

Z I Liu

Affiliations

Soon will be listed here.

Abstract

The recurrence and metastasis of cervical cancer contribute to a poor prognosis. The aim of this study was to investigate the risk factors for cervical cancer progression. A total of 284 patients with recurrent cervical cancer were retrospectively recruited to evaluate the association of disease recurrence with clinicopathological data. The univariate analysis demonstrated that patient age, tumor appearance and tumor size were significantly associated with early recurrence and metastasis of the disease (P<0.05). However, clinical stage, tumor histology, pathological stage and initial treatment options were not associated with early recurrence and metastasis of cervical cancer (P>0.05). The multivariate analysis also demonstrated that patient age, tumor appearance and tumor size were independent risk factors for the early recurrence of cervical cancer (P<0.05). Therefore, these three factors should be taken into consideration in the management of cervical cancer.

Citing Articles

Decoding the influence of external beam radiotherapy to brachytherapy duration and overall treatment on response and early recurrences in cervical cancer patients treated with chemoradiation.

Krishna A, Makkapatti B, Athiyamaan M, Lobo D, Srinivas C, Sunny J Radiat Oncol J. 2025; 42(4):257-262.

PMID: 39748526 PMC: 11701466. DOI: 10.3857/roj.2023.01025.

Nomogram for predicting 10-year postoperative recurrence of stage I gastric cancer.

Lyu T, Luo M, Hu H Transl Cancer Res. 2024; 13(10):5497-5508.

PMID: 39525020 PMC: 11543093. DOI: 10.21037/tcr-24-692.

Investigating and Analyzing Prognostic Factors and Their Impact on Recurrent Cervical Cancers.

Uke A, Dahake S, Luharia A, Luharia M, Mishra G, Mahakalkar C Cureus. 2024; 16(7):e65361.

PMID: 39184727 PMC: 11344604. DOI: 10.7759/cureus.65361.

Vaginal microbial profile of cervical cancer patients receiving chemoradiotherapy: the potential involvement of Lactobacillus iners in recurrence.

Wang Y, Wang T, Yan D, Zhao H, Wang M, Liu T J Transl Med. 2024; 22(1):575.

PMID: 38886729 PMC: 11184707. DOI: 10.1186/s12967-024-05332-2.

A prognostic model using FIGO 2018 staging and MRI-derived tumor volume to predict long-term outcomes in patients with uterine cervical squamous cell carcinoma who received definitive radiotherapy.

Zang L, Chen Q, Lin A, Chen J, Zhang X, Fang Y World J Surg Oncol. 2023; 21(1):210.

PMID: 37475053 PMC: 10360277. DOI: 10.1186/s12957-023-03116-4.

References

Armstrong E . Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010; 16(3):217-30. PMC: 10437588. DOI: 10.18553/jmcp.2010.16.3.217. View

Benedet J, Odicino F, Maisonneuve P, Beller U, Creasman W, Heintz A . Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2004; 83 Suppl 1:41-78. DOI: 10.1016/s0020-7292(03)90115-9. View

Goncalves A, Fabbro M, Lhomme C, Gladieff L, Extra J, Floquet A . A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 2007; 108(1):42-6. DOI: 10.1016/j.ygyno.2007.07.057. View

Estape R, Angioli R, Madrigal M, Janicek M, Gomez C, Penalver M . Close vaginal margins as a prognostic factor after radical hysterectomy. Gynecol Oncol. 1998; 68(3):229-32. DOI: 10.1006/gyno.1998.4960. View

Yang Y, Shen J, Tate J, Wang K, Su T, Wang K . Cervical cancer in young women in Taiwan: prognosis is independent of papillomavirus or tumor cell type. Gynecol Oncol. 1997; 64(1):59-63. DOI: 10.1006/gyno.1996.4543. View

Elst P, Ahankour F, Tjalma W . Management of recurrent cervical cancer. Review of the literature and case report. Eur J Gynaecol Oncol. 2008; 28(6):435-41. View

Morley G, Seski J . Radical pelvic surgery versus radiation therapy for stage I carcinoma of the cervix (exclusive of microinvasion). Am J Obstet Gynecol. 1976; 126(7):785-98. DOI: 10.1016/0002-9378(76)90668-2. View

Smaniotto D, DAgostino G, Luzi S, Valentini V, Macchia G, Mantini G . Concurrent 5-fluorouracil, mitomycin C and radiation with or without brachytherapy in recurrent cervical cancer: a scoring system to predict clinical response and outcome. Tumori. 2005; 91(4):295-301. DOI: 10.1177/030089160509100402. View

Classe J, Rauch P, Rodier J, Morice P, Stoeckle E, Lasry S . Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecol Oncol. 2006; 102(3):523-9. DOI: 10.1016/j.ygyno.2006.01.022. View

10.

Morice P, Uzan C, Zafrani Y, Delpech Y, Gouy S, Haie-Meder C . The role of surgery after chemoradiation therapy and brachytherapy for stage IB2/II cervical cancer. Gynecol Oncol. 2007; 107(1 Suppl 1):S122-4. DOI: 10.1016/j.ygyno.2007.07.015. View

11.

Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R . Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev. 2013; 2:35. PMC: 3681632. DOI: 10.1186/2046-4053-2-35. View

12.

Moore D . Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw. 2008; 6(1):53-7. DOI: 10.6004/jnccn.2008.0006. View

13.

Priebe A . 2012 cervical cancer screening guidelines and the future role of HPV testing. Clin Obstet Gynecol. 2013; 56(1):44-50. DOI: 10.1097/GRF.0b013e3182836b6a. View

14.

Hopkins M, Morley G . Radical hysterectomy versus radiation therapy for stage IB squamous cell cancer of the cervix. Cancer. 1991; 68(2):272-7. DOI: 10.1002/1097-0142(19910715)68:2<272::aid-cncr2820680210>3.0.co;2-x. View

15.

Peiretti M, Zapardiel I, Zanagnolo V, Landoni F, Morrow C, Maggioni A . Management of recurrent cervical cancer: a review of the literature. Surg Oncol. 2012; 21(2):e59-66. DOI: 10.1016/j.suronc.2011.12.008. View

16.

Mabuchi S, Isohashi F, Yoshioka Y, Temma K, Takeda T, Yamamoto T . Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer. 2010; 20(5):834-40. DOI: 10.1111/IGC.0b013e3181dcadd1. View

17.

Tao X, Hu W, Ramirez P, Kavanagh J . Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol. 2008; 110(3 Suppl 2):S67-71. DOI: 10.1016/j.ygyno.2008.04.024. View

18.

Cetina L, Garcia-Arias A, Candelaria M, Cantu D, Rivera L, Coronel J . Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients. World J Surg Oncol. 2009; 7:19. PMC: 2649933. DOI: 10.1186/1477-7819-7-19. View

19.

Keys H, Bundy B, Stehman F, Okagaki T, Gallup D, Burnett A . Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol. 2003; 89(3):343-53. DOI: 10.1016/s0090-8258(03)00173-2. View

20.

Cao L, Li X, Zhang Y, Li X, Wang Q . [Clinical features and prognosis of cervical cancer in young women]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010; 35(8):875-8. DOI: 10.3969/j.issn.1672-7347.2010.08.017. View